journal article·2019-12-04Open access

LINC01354 enhances the proliferation and invasion of lung cancer cells by regulating miR-340-5p/ATF1 signaling pathway

Gaojie Yang, Chongyi Yang, Yahui She, Zuojun Shen, Peng Gao

Abstract

Recent studies showed that long non-coding RNAs (lncRNAs) could play critical roles in tumors progression. However, the performance of LINC01354 is still limited in non-small cell lung cancer (NSCLC). In the current study, our results showed that LINC01354 was significantly increased in NSCLC tissues and cell lines. High LINC01354 expression was associated with advanced TNM stage and poor prognosis in NSCLC patients. Loss-of-function assays revealed that knockdown of LINC01354 reduced lung cancer cells proliferation and invasive ability in vitro. Subsequently, mechanism studies showed that LINC01354 positively regulated the ATF1 expression via competitive binding to miR-340-5p. Therefore, our results illustrated that LINC01354 might act as an oncogenic role by modulating the miR-340-5p/ATF1 axis, providing a novel therapeutic therapy for NSCLC treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer-related molecular mechanisms research · RNA modifications and cancer · Circular RNAs in diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pediatrics, Ninghai First Hospital

Department of Respiratory, Ninghai First Hospital

Department of Pediatrics, Ninghai Hospital, Branch of Shanghai Tenth People's Hospital

Department of Urology, Ninghai First Hospital

Clinical Laboratory, People's Hospital of Bozhou City

Anhui Provincial Center for Clinical Laboratories

References (24)

Show source-provided references
1. 10.3322/caac.2126210.3322/caac.21262 ↗
2. 10.1016/j.ccm.2011.09.00110.1016/j.ccm.2011.09.001 ↗
3. 10.1016/j.rcl.2012.06.00610.1016/j.rcl.2012.06.006 ↗
4. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship[C]//Mayo Clinic Proceedings. Elsevier. 2008;83(5):584–594.
5. 10.1016/j.cell.2009.02.00610.1016/j.cell.2009.02.006 ↗
6. 10.1016/j.molcel.2011.08.01810.1016/j.molcel.2011.08.018 ↗
7. 10.1016/j.tcb.2011.04.00110.1016/j.tcb.2011.04.001 ↗
8. 10.1007/s13277-014-2925-610.1007/s13277-014-2925-6 ↗
9. 10.1371/journal.pone.007399110.1371/journal.pone.0073991 ↗
10. 10.1042/BSR2018037510.1042/BSR20180375 ↗
11. 10.1186/s13046-019-1150-y10.1186/s13046-019-1150-y ↗
12. 10.1016/j.ijbiomac.2019.02.08310.1016/j.ijbiomac.2019.02.083 ↗
13. 10.1038/s41419-019-1479-310.1038/s41419-019-1479-3 ↗
14. Huang C, Liu S, Wang H, et al. LncRNA PVT1 overexpression is a poor prognostic biomarker and regulates migration and invasion in small cell lung cancer. Am J Transl Res. 2016;8(11):5025.
15. 10.3892/or.2016.510510.3892/or.2016.5105 ↗
16. 10.1016/j.biopha.2018.02.13010.1016/j.biopha.2018.02.130 ↗
17. 10.2147/CMAR.S17873210.2147/CMAR.S178732 ↗
18. 10.1002/cam4.215010.1002/cam4.2150 ↗
19. 10.1038/nature1298610.1038/nature12986 ↗
20. 10.1016/j.biopha.2018.05.04610.1016/j.biopha.2018.05.046 ↗
21. 10.1080/21691401.2019.157788310.1080/21691401.2019.1577883 ↗
22. 10.1016/j.abb.2014.07.01210.1016/j.abb.2014.07.012 ↗
23. 10.1002/cncr.2586010.1002/cncr.25860 ↗
24. 10.1038/onc.2014.26710.1038/onc.2014.267 ↗